As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Apalutamide in patients with non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
This review discusses its pharmacological properties, dosage and administration, efficacy and tolerability, and evidence in support of the use of Apalutamide as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr Laurence Krieger, a Consultant General Physician at Royal North Shore Hospital and Clinical Lecturer with the University of Sydney.
Please login below to download this issue (PDF)